Urine Peptidomics for Clinical Biomarker Discovery

Advances in Clinical Chemistry

Volumn 51, Issue C, 2010, Pages 181-213

  Ling, Xuefeng B ^a   Mellins, Elizabeth D ^a   Sylvester, Karl G ^a   Cohen, Harvey J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Biomarker; Biomarker panel; Diagnosis; False discovery rate; Peptidome; Prognosis; Proteomic profile; Urine peptide

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE;

AMINO ACID SEQUENCE; BOOK; HUMAN; LABORATORY DIAGNOSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR GENETICS; PROTEOMICS; TANDEM MASS SPECTROMETRY; URINE;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEOMICS; SPECIMEN HANDLING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77955948010     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(10)51007-2     Document Type: Book

References (53)

1. Brenner B.M., Rector F.C., Levine S.A. Brenner and Rector's The Kidney 2004, Saunders, Philadelphia. 7 ed.
2. Strong K.J., Osicka T.M., Comper W.D. Urinary-peptide excretion by patients with and volunteers without diabetes. J. Lab. Clin. Med. 2005, 145:239-246.
3. Decramer S., de Peredo A.G., Breuil B., Mischak H., Monsarrat B., Bascands J.-L., et al. Urine in Clinical Proteomics. Mol. Cell. Proteomics 2008, 7:1850-1862.
4. Schulz-Knappe P., Schrader M., Standker L., Richter R., Hess R., Jurgens M., et al. Peptide bank generated by large-scale preparation of circulating human peptides. J. Chromatogr. A 1997, 776:125-132.
5. Cutillas P.R., Norden A.G., Cramer R., Burlingame A.L., Unwin R.J. Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. Clin. Sci. (Lond.) 2003, 104:483-490.
6. Hardouin J. Protein sequence information by matrix-assisted laser desorption/ionization in-source decay mass spectrometry. Mass Spectrom. Rev. 2007, 26:672-682.
7. Shadforth I., Crowther D., Bessant C. Protein and peptide identification algorithms using MS for use in high-throughput, automated pipelines. Proteomics 2005, 5:4082-4095.
8. Mortz E., O'Connor P.B., Roepstorff P., Kelleher N.L., Wood T.D., McLafferty F.W., et al. Sequence tag identification of intact proteins by matching tanden mass spectral data against sequence data bases. Proc. Natl. Acad. Sci. USA 1996, 93:8264-8267.
9. Balgley B.M., Laudeman T., Yang L., Song T., Lee C.S. Comparative evaluation of tandem MS search algorithms using a target-decoy search strategy. Mol. Cell. Proteomics 2007, 6:1599-1608.
10. Sadygov R.G., Cociorva D., Yates J.R. Large-scale database searching using tandem mass spectra: looking up the answer in the back of the book. Nat. Methods 2004, 1:195-202. 3rd.
11. Coon J.J., Zurbig P., Dakna M., Dominiczak A.F., Decramer S., Fliser D., et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin. Appl. 2008, 2:964-973.
12. Adachi J., Kumar C., Zhang Y., Olsen J.V., Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006, 7:R80.
13. Decramer S., Gonzalez de Peredo A., Breuil B., Mischak H., Monsarrat B., Bascands J.L., et al. Urine in clinical proteomics. Mol. Cell. Proteomics 2008, 7:1850-1862.
14. Ling X.B., Sigdel T.K., Lau K., Ying L., Lau I., Schilling J., et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J. Am. Soc. Nephrol. 2010, 21:646-653.
15. Snyder S.L., Sobocinski P.Z. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 1975, 64:284-288.
16. Mi H., Lazareva-Ulitsky B., Loo R., Kejariwal A., Vandergriff J., Rabkin S., et al. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 2005, 33:D284-8.
17. Zimmerli L.U., Schiffer E., Zurbig P., Good D.M., Kellmann M., Mouls L., et al. Urinary Proteomic Biomarkers in Coronary Artery Disease. Mol. Cell. Proteomics 2008, 7:290-298.
18. Wittke S., Haubitz M., Walden M., Rohde F., Schwarz A., Mengel M., et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant. 2005, 5:2479-2488.
19. Quintana L.F., Campistol J.M., Alcolea M.P., Banon-Maneus E., Sole-Gonzalez A., Cutillas P.R. Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol. Cell. Proteomics 2009, 8:1658-1673.
20. Jantos-Siwy J., Schiffer E., Brand K., Schumann G., Rossing K., Delles C., et al. Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. J. Proteome Res. 2009, 8:268-281.
21. Rossing K., Mischak H., Dakna M., Zurbig P., Novak J., Julian B.A., et al. Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19:1283-1290.
22. Rossing K., Mischak H., Parving H.H., Christensen P.K., Walden M., Hillmann M., et al. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int. 2005, 68:193-205.
23. Decramer S., Wittke S., Mischak H., Zurbig P., Walden M., Bouissou F., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 2006, 12:398-400.
24. Theodorescu D., Wittke S., Ross M.M., Walden M., Conaway M., Just I., et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006, 7:230-240.
25. Theodorescu D., Schiffer E., Bauer H.W., Douwes F., Eichhorn F., Polley R., et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin. Appl. 2008, 2:556-570.
26. Theodorescu D., Fliser D., Wittke S., Mischak H., Krebs R., Walden M., et al. Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26:2797-2808.
27. Sigdel T., Ling X.B., Lau K., Li L., Schilling J., Sarwal M. Urinary peptidomic analysis identifies potential biomarkers for acute rejection of renal transplantation. Clin. Proteomics 2009, 5:103-113.
28. Ong S.E., Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005, 1:252-262.
29. Turck C.W., Falick A.M., Kowalak J.A., Lane W.S., Lilley K.S., Phinney B.S., et al. The Association of Biomolecular Resource Facilities Proteomics Research Group 2006 study: relative protein quantitation. Mol. Cell. Proteomics 2007, 6:1291-1298.
30. Yasui Y., Pepe M., Thompson M.L., Adam B.L., Wright, G.L., Qu Y., et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003, 4:449-463.
31. Tibshirani R., Hastie T., Narasimhan B., Soltys S., Shi G., Koong A., et al. Sample classification from protein mass spectrometry, by 'peak probability contrasts'. Bioinformatics 2004, 20:3034-3044.
32. Addona T.A., Abbatiello S.E., Schilling B., Skates S.J., Mani D.R., Bunk D.M., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27:633-641.
33. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5:573-588.
34. Santambrogio S., Cattaneo A., Bernascone I., Schwend T., Jovine L., Bachi A., et al. Urinary uromodulin carries an intact ZP domain generated by a conserved C-terminal proteolytic cleavage. Biochem. Biophys. Res. Commun. 2008, 370:410-413.
35. Peng X., Wood C.L., Blalock E.M., Chen K.C., Landfield P.W., Stromberg A.J. Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinform. 2003, 4:26.
36. Kendziorski C., Irizarry R.A., Chen K.S., Haag J.D., Gould M.N. On the utility of pooling biological samples in microarray experiments. Proc. Natl. Acad. Sci. USA 2005, 102:4252-4257.
37. Kendziorski C.M., Zhang Y., Lan H., Attie A.D. The efficiency of pooling mRNA in microarray experiments. Biostatistics 2003, 4:465-477.
38. Jolly R.A., Goldstein K.M., Wei T., Gao H., Chen P., Huang S., et al. Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants. Physiol. Genomics 2005, 22:346-355.
39. Sadiq S.T., Agranoff D. Pooling serum samples may lead to loss of potential biomarkers in SELDI-ToF MS proteomic profiling. Proteome Sci. 2008, 6:16.
40. Annesley T.M. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49:1041-1044.
41. Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99:6567-6572.
42. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRSSB 1995, 57:289-300.
43. Efron B., Tibshirani R., Storey J., Tusher V. Empirical bayes analysis of microarray experiment. J. Am. Stat. Assoc. 2001, 96:1151-1160.
44. Ling X.B., Cohen H., Jin J., Lau I., Schilling J. FDR made easy in differential feature discovery and correlation analyses. Bioinformatics 2009, 25:1461-1462.
45. Holman R.C., Stoll B.J., Curns A.T., Yorita K.L., Steiner C.A., Schonberger L.B. Necrotising enterocolitis hospitalisations among neonates in the United States. Paediatr. Perinat. Epidemiol. 2006, 20:498-506.
46. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.
47. Sing T., Sander O., Beerenwinkel N., Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941.
48. Wallace C.A., Levinson J.E. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. N. Am. 1991, 17:891-905.
49. Cassidy J., Petty R. Textbook of Pediatric Rheumatology 2001, W.B. Saunders Company, Philadelphia. 4 ed.
50. Kimura Y., Pinho P., Walco G., Higgins G., Hummell D., Szer I., et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2005, 32:935-942.
51. Horneff G., Schmeling H., Biedermann T., Foeldvari I., Ganser G., Girschick H.J., et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 2004, 63:1638-1644.
52. Lequerre T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 2008, 67:302-308.
53. Gattorno M., Chicha L., Gregorio A., Ferlito F., Rossi F., Jarrossay D., et al. Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue. Rheumatology (Oxford) 2007, 46:657-665.